Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart FailurePRNewsWire • 08/06/20
Precigen to Announce Second Quarter and First Half 2020 Financial Results on August 10thPRNewsWire • 08/03/20
Precigen to Participate in Upcoming JMP Securities Hematology and Oncology ForumPRNewsWire • 06/11/20
Notice: Precigen Announces Date and Location Change for its 2020 Annual Meeting of ShareholdersPRNewsWire • 06/04/20
8 Stocks That Could Double From 2020 to 2021, With No COVID-19 Focus at All24/7 Wall Street • 05/29/20
Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/07/20